Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Cancer Immunol Res. 2019 May 31;7(7):1202–1213. doi: 10.1158/2326-6066.CIR-18-0498

Figure 3. Presence of anti-HPV E6/E7 epitope CD8+ T cell responses in HPV+ OPSCC tumors.

Figure 3

Tumors from HPV+ OPSCC patients were assessed for the presence of CD8+ T cell responses to the HLA-A*0201 restricted HPV E6/E7 epitopes, LLMGTLGIV (LV9), TIHDIILECV (TV10), and KLPQLCTEL (KL9) using dextramers. (A) A representative dot plot showing the presence of all three reactivities in a tumor. (B) Quantification of responses to all three epitopes (LV9, TV10 and KL9) from five HPV+ OPSCC tumors.